<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770274</url>
  </required_header>
  <id_info>
    <org_study_id>1316/15-2-16</org_study_id>
    <nct_id>NCT02770274</nct_id>
  </id_info>
  <brief_title>Cilostazol Following Peripheral Endovascular Procedures</brief_title>
  <acronym>CILO-PER</acronym>
  <official_title>Multi-center, Randomized Trial Comparing Dual Antiplatelet Therapy With CILOstazol Plus Aspirin Versus Aspirin Alone Following PERipheral Endovascular Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Patras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Attikon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg
      twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients
      undergoing peripheral angioplasty or stenting or both for the management of peripheral
      arterial disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, single-blinded, phase III, controlled trial investigating
      the safety and effectiveness of dual antiplatelet therapy with cilostazol 100 mg twice daily
      and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing
      peripheral, infrainguinal angioplasty or stenting or both for the management of peripheral
      arterial disease (intermittent claudication or critical limb ischemia). The study will
      include in total 200 patients randomized on a 1:1 basis to receive either dual antiplatelet
      therapy for 6 months cilostazol 100 mg once daily and aspirin 100 mg daily versus monotherapy
      with aspirin 100 mg daily for 12 months. The study's primary endpoint will be the composite
      of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke,
      major amputation, target limb open surgical or endovascular revascularization). Additional
      therapy with clopidogrel 75mg daily will be added in either group for one month in case of
      stent placement. Secondary endpoints will include quality of life assessment using dedicated
      questionnaires, drug- and procedure-related complication rates, target-limb revascularization
      rates, clinical improvement (ABI and Rutherford-Becker classification changes). Clinical
      follow up will be performed at 1, 6 and 12 months and will include physical examination, ABI
      measurements, Rutherford-Becker classification. Maximum follow up period will be 2 years
      after the index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of major adverse cardiovascular and limb events</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug-related complications</measure>
    <time_frame>1 year</time_frame>
    <description>Major and minor drug-related complications (including bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>1-year</time_frame>
    <description>Clinical improvement of target limb according to Rutherford-Becker classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of quality of life changes during follow up period using dedicated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related complications</measure>
    <time_frame>1 month</time_frame>
    <description>Minor and major procedure-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI) changes</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Ankle-Brachial Index (ABI) measurements during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cholesterol level monitoring</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Blood test to monitor cholesterol levels during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level monitoring</measure>
    <time_frame>6-12 months</time_frame>
    <description>Blood test to monitor glucose levels during follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Group Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving monotherapy with aspirin 100mg once daily for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Dual therapy with Cilostazol 100 mg twice daily</description>
    <arm_group_label>Group Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Monotherapy with aspirin 100 mg once daily</description>
    <arm_group_label>Group Cilostazol</arm_group_label>
    <arm_group_label>Group Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled infrainguinal (femoropopliteal or infrapopliteal or both) angioplasty and/or
             stenting.

          -  Surgical or endovascular treatment of Inflow iliac artery significant stenosis if
             deemed necessary.

          -  Symptomatic severe intermittent claudication (Rutherford-Becker 3) or critical limb
             ischemia (Rutherford-Becker 4-6).

          -  Informed consent signed

        Exclusion Criteria:

          -  Any contraindication to aspirin or cilostazol intake

          -  No pedal arch outflow

          -  Sole iliac artery treatment

          -  Standard contraindications to angioplasty

          -  Acute or sub-acute limb ischemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Brountzos, MD, PhD, EBIR</last_name>
    <role>Study Chair</role>
    <affiliation>2nd Department of Radiology, Interventional Radiology Unit, National and Kapodestrian University of Athens, Attikon University General Hospital, Athens, Greece.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stavros Spiliopoulos, MD, PhD, EBIR</last_name>
    <phone>+306937403468</phone>
    <email>stavspiliop@med.uoa.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lazaros Reppas, MD</last_name>
    <phone>+306947217995</phone>
    <email>l.reppas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Patras Universityu Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitris Karnabatidis, MD, PhD</last_name>
      <phone>+302613603</phone>
      <phone_ext>219</phone_ext>
      <email>karnaby@med.upatras.gr</email>
    </contact>
    <contact_backup>
      <last_name>Panagiotis Kitrou, MD, PhD</last_name>
      <phone>+302613603</phone>
      <phone_ext>218</phone_ext>
      <email>panoskitrou@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dimitris Karnabatidis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panagiotis Kitrou, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kostantinos Katsanos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon university General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>15343</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stavros Spiliopoulos, MD, PhD</last_name>
      <phone>+30210581</phone>
      <phone_ext>1832</phone_ext>
      <email>stavspiliop@med.uoa.gr</email>
    </contact>
    <contact_backup>
      <last_name>Lazaros Reppas, MD</last_name>
      <phone>+3021058</phone>
      <phone_ext>1844</phone_ext>
      <email>l.reppas@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elias Brountzos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stavros Spiliopoulos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lazaros Reppas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Tsitskari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Geroulakos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Kakkisis, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Lazaris, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Attikon Hospital</investigator_affiliation>
    <investigator_full_name>Stavros Spiliopoulos</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

